Metastatic malignant melanoma

Drugs of Today

Volumn 39, Issue SUPPL. C, 2003, Pages 17-38

  Meric, J B ^a   Rixe, O ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; BRYOSTATIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; FLUOROURACIL; FOTEMUSTINE; HISTAMINE; IMMUNOMODULATING AGENT; LOMUSTINE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; SEMUSTINE; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIRAPAZAMINE; TUMOR NECROSIS FACTOR; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; HUMAN; IMMUNOMODULATION; KILLER CELL; MELANOMA; META ANALYSIS; METASTASIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN;

EID: 0344667699     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (162)

1. Hill, G.J., Krementz, E.T., Hill, H.Z. Dimethyl triazenoimidazole carboxamide and combination therapy for melanoma stage IV. Late results after complete response to chemotherapy. Cancer 1984, 53: 1299-305.
2. Jacquillat, C., Khayat, D., Banzet, P. et al. Final report on a French multicenter phase II study of the nitrosoureas fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66: 1873-8.
3. Khayat, D., Avril, M.F., Auclerc, G. et al. Clinical value of the nitrosoureas fotemustine in disseminated malignant melanoma, overview on 1022 patients including 144 patients with cerebral metastases. Proc Am Soc Clin Oncol 1993, 12: 1343.
4. Lotze, M.T., Dallal, R.M., Kirkwood, J.M. et al. Cutaneous melanoma. In: De Vita, V.T., Helmann, S., Rosenberg, S.A. (Eds.). Cancer, Principles and Practice of Oncology. JB Lippincott: Philadelphia 2001, 2012-86.
5. Al-Sarraf, M., Fletcher, W., Oishi, N. et al. Cisplatin hydratation with and without mannitol diuresic in refractory disseminated malignant melanoma, a South West Oncology Group study. Cancer Treat Rep 1982, 66: 31-3.
6. Schilcher, R.B., Wessens, M., Niderle, M. et al. Phase II evaluation of fractionated of low and single high dose cisplatin in various tumors. J Cancer Res Clin Oncol 1984, 107: 57-60.
7. Song, S.Y., Chary, K.K., Higby, D.J. et al. Cisdiaminedichloride platinum (11) in the treatment of metastatic malignant melanoma. Clin Res 1977, 25: 411.
8. Khayat, D., Coeffic, D., Antoine, E.C. Overview of medical treatments of metastatic malignant melanoma. In: Educational Book. Am Soc Clin Oncol 2000, 414-27.
9. Rowinsky, E.K., MacGuire, W.P. Taxol, present status and future prospects. Contemp Oncol 1991, 29-36.
10. Aamdal, S., Wolff, I., Kaplan, S. et al. Docetaxel (Taxotere) in advanced malignant melanoma, a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994, 8: 1061-4.
11. Bedikian, A., Legha, S., Genkins, J. et al. Phase II trial of docetaxel in patients (pts) with advanced melanoma previously untreated with chemotherapy. Proc Am Soc Clin Oncol 1995, 14: 1304.
12. Retsas, S., Peat, E., Ashford, R. et al. Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma. J Cancer Clin Oncol 1982, 18: 1293-5.
13. Dancey, J., Steward, W.P. The role of vindesine in oncology-recommendations after 10 years' experience. Anti-cancer Drugs 1995, 6: 625-36.
14. Bedikian, A.Y., Plager, C., Stewart, J.R. et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 2001, 11: 183-8.
15. Middleton, M.R., Gore, M., Tilgen, W. et al. A randomized phase III study of temozolomide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced metastatic melanoma. Proc Am Soc Clin Oncol 1999, 18: 536a.
16. Aamdal, S., Avril, M.F., Grob, J.J. et al. A phase III randomized trial of fotemustine (F) versus dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without brain metastases. Proc Am Soc Clin Oncol 2001, 21: 1361.
17. Young, D.W., Lever, R.S., English, J.S. et al. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer 1985, 55: 1879-81.
18. Seigler, H.F., Lucas, V.S., Jr., Pickett, N.J. et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980, 46: 2346-8.
19. Mulder, J.H., Dodion, P., Cavalli, F. et al. Cisplatin and vindesine combination chemotherapy in advanced malignant melanoma: An EORTC phase II study. Eur J Cancer Clin Oncol 1982, 18: 1297-301.
20. Del Prete, S.A., Maurer, L.H., O'Donnell, J. et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984, 68: 1403-5.
21. Ringborg, U., Jungnelius, U., Hansson, J. et al. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial. Am J Clin Oncol 1990, 13: 214-7.
22. York, R.M., Foltz, A.T. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1988, 61: 2183-6.
23. Avril, M.F., Bonneterre, J., Cupissol, D. et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992, 11: 1807-11.
24. Buzaid, A.C., Legha, S., Winn, R. et al. Cisplatin, vinblastine and dacarbazine alone in metastatic melanoma, preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol 1993, 12: 1328.
25. McClay, E.F., Mastrangelo, M.J., Sprandio, J.D. et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989, 63: 1292-5.
26. Comella, G., Daponte, A., Comella, P. et al. Combination chemotherapy with vinblastine, BCNU and cisplatin in advanced metastatic melanoma. Tumori 1991, 77: 216-8.
27. Fletcher, W.S., Daniels, D.S., Sondak, V.K. et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol 1993, 16: 359-62.
28. Icli, F., Karaoguz, H., Dincol, D. et al. Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin. J Surg Oncol 1991, 48: 199-201.
29. Murren, J.R., DeRosa, W., Durivage, H.J. et al. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-7.
30. Steffens, T., Bajorin, D.F., Chapman, P.B. et al. A phase II trial of high-dose cisplatin and dacarbazine. Cancer 1991, 68: 1230-7.
31. Olver, I.N., Bishop, J.F., Green, M. et al. A phase II study of cisplatinum and continuous infusion 5-fluorouracil for metastatic melanoma. Am J Clin Oncol 1992, 15: 503-5.
32. Richard, M.A., Grob, J.J., Zarrour, H. et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Res 1998, 8: 170-4.
33. Rixe, O., Borel, C., Paraiso, D. et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: A phase II study of 43 patients. Melanoma Res 1995, 5: 419-24.
34. Margolin, K.A., Liu, P.Y., Flaherty, L.E. et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 1998, 16: 664-9.
35. Seeber, A., Binder, M., Steiner, A. et al. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer 1998, 34: 2129-31.
36. Semb, K.A., Aamdal, S., Bohmann, T. et al. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma Res 1998, 8: 565-72.
37. Gander, M., Leyvraz, S., Decosterd, L. et al. Sequential administration of temozolomide and fotemustine: Depletion of 06-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 1999, 10: 831-8.
38. Bedikian, A.Y., Legha, S.S., Eton, O. et al. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anti-cancer Drugs 1999, 10: 735-9.
39. Bafaloukos, D., Gogas, H., Georgoulias, V. et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002, 20: 420-5.
40. Bafaloukos, D., Aravantinos, G., Fountzilas, G. et al. Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology 2002, 63: 333-7.
41. Carey, R.W., Anderson, J.R., Green, M. et al. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine and cisplatin, a report from the Cancer and Leukemia Group B. Cancer Treat Rep 1986, 70: 329-31.
42. Ringborg, U., Rundenstam, C.M., Hansson, J. et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma, a randomized phase II study. Med Oncol Tumor Pharmacother 1989, 6: 285-9.
43. Luikart, S.D., Kennealey, G.T., Kirkwood, J.M. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiamine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984, 2: 164-8.
44. Van Dyk, J.J., Falkson, G. A clinical trial of procarbazine plus vincristine plus bischloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma. Med Pediatr Oncol 1975, 1: 107-11.
45. Bellet, R.E., Catalano, R.B., Mastrangelo, M.J. et al. Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. Cancer Treat Rep 1978, 62: 2095-9.
46. Chapman, P.B., Einhorn, L.H., Meyers, M.L. et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17: 2745-51.
47. Jansen, B., Wachek, V., Here-Ress, E. et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 18: 1728-33.
48. Hwu, W.J., Krown, S.E., Menall, J.H. et al. Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma, a phase II trial. Proc Am Soc Clin Oncol 2002, 21: 1372.
49. Mac Clay, E.F., Mastrangelo, M.J., Bellet, R.E. et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987, 71: 465-9.
50. Thomson, D.B., Adena, M., McLeod, G.R. et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial. Melanoma Res 1993, 3: 133-8.
51. McKeage, M.J., Lorentzos, A., Gore, M.E. Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. N Engl J Med 1993, 328: 140-1.
52. Flaherty, L.E., Liu, P.Y., Mitchell, M.S. et al. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). Am J Clin Oncol 1996, 19: 108-13.
53. Semb, K.A., Aamdal, S., Bohmann, T. et al. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma Res 1998, 8: 565-72.
54. Schultz, M.Z., Buzaid, A.C., Poo, W.J. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res 1997, 7: 147-51.
55. Feun, L.G., Savaraj, N., Moffat, F. et al. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 1995, 5: 273-6.
56. Gause, B.L., Sharfman, W.H., Janik, J.E. et al. A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Invest 1998, 16: 374-80.
57. McClay, E.F., McClay, M.T., Monroe, L. et al. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res 2001, 11: 309-13.
58. O'Neill, P., Hersh, E., Warneke, J. et al. Phase II trial of combination chemotherapy and biological response modification in metastatic melanoma. Proc Am Soc Clin Oncol 1996, 432b, A 1338.
59. Nathan, F.E., Berd, D., Sato, T. et al. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer 2000, 88: 79-87.
60. Margolin, K.A., Liu, P.Y., Unger, J.M. et al. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: A Southwest Oncology Group trial. J Cancer Res Clin Oncol 1999, 125: 292-6.
61. Saba, H.I., Cruse, C.W., Wells, K.E. et al. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: A University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 1992, 28: 65-9.
62. Lattanzi, S.C., Tosteson, T., Chertoff, J. et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995, 5: 365-9.
63. Spitler, L., Good, J., Jacobs, M. et al. The use of high dose tamoxifen to potentiate the anti-tumor effects of cytotoxic chemotherapy in patients with metastatic melanoma. Proc Am Soc Clin Oncol 1994, 397: 1353.
64. Rusthoven, J.J., Kuirt, I.C., Iscoe, N.A. et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma, National Cancer Institute of Canada Trials Group. J Clin Oncol 1996, 14: 2083-90.
65. Falkson, C.I., Ibrahim, J., Kirkwood, J.M. et al. Phase III trial of dacarbazine versus dacarbazine with alfa-interferon 2b versus dacarbazine with tamoxifen versus dacarbazine with alfa-interferon 2b and tamoxifen in patients with metastatic melanoma, an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16: 1743-51.
66. Falkson, C.I., Falkson, G., Falkson, H.C. Improved results with the edition of interferon-alfa2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991, 9: 1403-8.
67. Cocconi, G., Bella, M., Calabresi, F. et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992, 327: 516-23.
68. Legha, S., Ring, S., Bedikian, A. et al. Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha-Interferon (IFN) in patients (PT) with metastatic melanoma (MM). Proc Am Soc Clin Oncol 1993, 388: 1325.
69. Agarwala, S.S., Ferri, W., Gooding, W. et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999, 85: 1979-84.
70. Bajetta, E., Buzzoni, R., Vicario, G. et al. Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine. Tumori 1995, 81: 238-40.
71. Rusthoven, J.J., Quirt, I.C., Iscoe, N.A. et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996, 14: 2083-90.
72. Chiarion Sileni, V., Nortilli, R., Medici, M. et al. BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): Results of a randomized Phase II study. Proc Am Soc Clin Oncol Congr 1997: Abst 1782.
73. Kirkwood, J.M. Studies of interferons in the therapy of melanoma. Semin Oncol 1991, 18: 83-9.
74. Legha, S. Current therapy for melanoma. Semin Oncol 1989, 16: 34-44.
75. Lindemann, A., Brossart, P., Hoffken, K. et al. Immunomodulatory effects of ultradose interleukin-2 in cancer patients, a phase Ib study. Cancer Immunol Immunother 1993, 37: 307-15.
76. Rosenberg, S.A., Lotze, M.T., Muul, N.N. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987, 16: 889-97.
77. Dutcher, J.P., Creekmore, S., Weiss, G.R. et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989, 7: 477-85.
78. West, W.H., Tauer, K.W., Yannelli, J.R. et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987, 15: 898-905.
79. Gaynor, E.R., Weiss, G.R., Margolin, K.A. et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990, 82: 1397-402.
80. Bar, M.H., Sznol, M., Atkins, M.B. et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990, 8: 1138-47.
81. Richards, J.M., Barker, E., Latta, J. et al. Phase I study of weekly 24-hour infusions of recombinant human interleukin-2. J Natl Cancer Inst 1988, 80: 1325-8.
82. Parkinson, D.R., Abrams, J.S., Wiernik, P.H. et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990, 8: 1650-6.
83. Dillman, R.O., Oldham, R.K., Tauer, K.W. et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group Trial. J Clin Oncol 1991, 9: 1233-40.
84. Dutcher, J.P., Gaynor, E.R., Boldt, D.H. et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991, 9: 641-8.
85. McCabe, M., Stablein, D., Hawkins, M.J. et al. The modified group-C experience-phase III randomized trials of interleukin-2 vs interleukin-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol Congr 1991, 10: 714.
86. Rosenberg, S.A., Lotze, M.T., Yang, J.C. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85: 622-32.
87. Rosenberg, S.A., Lotze, M.T., Yang, J.C. et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210: 474-84.
88. Thatcher, N., Dazzi, H., Johnson, R.J. et al. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer 1989, 60: 770-4.
89. Parkinson, D.R., Abrams, J.S., Wiernik, P.H. et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990, 8: 1650-6.
90. Dorval, T., Mathiot, C., Chosidow, O. et al. IL-2 phase II trial in metastatic melanoma: Analysis of clinical and immunological parameters. Biotechnol Ther 1992, 3: 63-79.
91. Pérez, E.A., Scudder, S.A., Meyers, F.A. et al. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study. J Immunother 1991, 10: 57-62.
92. Whitehead, R.P., Kopecky, K.J., Samson, M.K. et al. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 1991, 83: 1250-2.
93. Koretz, M.J., Lawson, D.H., York, R.M. et al. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991, 126: 898-903.
94. Sparano, J.A., Fisher, R.I., Sunderland, M. et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11: 1969-77.
95. Rosenberg, S.A., Yannelli, J.R., Yang, J.C. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86: 1159-66.
96. Antoine, E.C., Benhammouda, A., Bernard, A. et al. Salpêtriè t'e Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997, 3: S16-S21.
97. Schwartzentruber, D.J., Hom, S.S., Dadmarz, R. et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994, 12: 1475-83.
98. Dillman, R.O., Oldham, R.K., Barth, N.M. et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991, 68: 1-8.
99. Kradin, R.L., Kurnick, J.T., Lazarus, D.S. et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989, 1: 577-80.
100. Mizoguchi, H., O'Shea, J.J., Longo, D.L. et al. Alterations in signal transduction molecules in T-lymphocytes from tumor-bearing mice. Science 1992, 258: 1795-8.
101. Kono, K., Salazar-Onfray, F., Petersson, M. et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal transducing zeta-molecules and inhibits tumor-specific T cell and natural killer cell mediated cytotoxicity. Eur J Immunol 1996, 26: 1308-13.
102. Hellstrand, K., Asca, A., Dahlgren, C. et al. Histaminergic regulation of NK cells, role of monocyte-derived reactive oxygen metabolites. J Immunol 1994, 153: 4940-7.
103. Hansson, M., Hermodsson, S., Brune, M. et al. Histamine protects T cells and natural-killer cells against oxidative stress. J Interferon Cytokine Res 1999, 19: 1135-44.
104. Hellstrand, K., Hermodsson, S. Cell to cell mediated inhibition of natural-killer cell proliferation by monocytes and its regulation by histamine H2 receptors. Scand J Immunol 1991, 34: 741-52.
105. Hellstrand, K., Hermodsson, S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990, 92: 379-89.
106. Asca, A., Hermodsson, S., Hellstrand, K. Histaminergic regulation of natural-killer cell-mediated clearance of tumor cells in mice. Scand J Immunol 1996, 43: 9-15.
107. Hellstrand, K., Naredi, P., Lindner, P. et al. Histamine in immunotherapy of advanced melanoma, a pilot study. Cancer Immunol Immunother 1994, 39: 416-9.
108. Agarwala, S.S., Glaspy, J., O'Day, S.J. et al. Results from a randomized phase III study comparing combined treatment with histamine dihidrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002, 20: 125-33.
109. Whitehead, R.P., Figlin, R., Citron, M.L. et al. A phase II trial of concomitant human interleukin-2 and interferon alfa-2a in patients with disseminated malignant melanoma. J Immunother 1993, 13: 117-21.
110. Rosenberg, S.A., Lotze, M.T., Yang, J.C et al. Combination therapy with interleukin-2 and alfa-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989, 7: 1863-74.
111. Sparano, J.A., Fisher, R.I., Sunderland, M. et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11: 1969-77.
112. Berd, D., MaGuire, H.C., Jr., Mastrangelo, M.J. Potentiation of human cell-mediated and humoral immunity by low dose cyclophosphamide. Cancer Res 1984, 44: 5439-43.
113. Ehrke, M.J., Mihich, E., Berd, D. et al. Effects of anti-cancer drugs on the immune system in humans. Semin Oncol 1989, 16: 230-53.
114. Chabot, G.G., Flaherty, L.E., Valdivieso, M. et al. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 1990, 27: 157-60.
115. Buzaid, A.C., Handerson, C.M., Ali Osman, F. et al. Biochemotherapy in the treatment of advanced melanoma, clinical results and potential mechanisms of anticancer activity. Prog Anti-cancer Treat 1997, 68: 87.
116. Richner J, Joss RA, Goldhirsch A. et al. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992, 28A: 1044-7.
117. Margolin, K.A., Doroshow, J.H., Akman, S.A. et al. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 1992, 10: 1574-8.
118. Stark, J.J., Dillman, R.O., Schulof, R. et al. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: Final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer 1998, 82: 1677-81.
119. Bajetta, E., Negretti, E., Giannotti, B. et al. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 1990, 13: 405-9.
120. Mulder, N.H., Willemse, P.H., Schraffordt Koops, H. et al. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer 1990, 62: 1006-7.
121. Comella, P., Daponte, A., Casaretti, R. et al. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in the treatment of advanced melanoma. Eur J Cancer 1997, 33: 1326-9.
122. Sondak, V.K., Liu, P.Y., Flaherty, L.E. et al. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: A Southwest Oncology Group study. Cancer J Sci Am 1999, 5: 41-7.
123. Daponte, A., Ascierto, P.A., Gravina, A. et al. Italian Cooperative Oncology Group. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000, 89: 2630-6.
124. Ridolfi, R., Tanganelli, L., Scelzi, E. et al. Italian Melanoma Intergroup. Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea. J Chemother 2003, 15: 198-202.
125. Papadopoulos, N.E.J., Howard, J.G., Murray, J.L. et al. Phase II DTIC and interleukin-2 trial for metastatic malignant melanoma. Proc Am Soc Clin Oncol 1990, 9: 277a.
126. Dillman, R.O., Oldham, R.K., Barth, N.M. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma, a National Biotherapy Study Group trial. J Natl Cancer Inst 1990, 82: 1345-9.
127. Tamm, I., Grimme, H., Bergen, E. et al. Dacarbazine and interferon-alfa stage IV malignant melanoma. Oncology 1997, 54, 270-4.
128. Demchak, P.A., Mier, J.W., Robert, N.J. et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma, a pilot study. J Clin Oncol 1991, 9: 1821-30.
129. Blair, S., Flaherty, L., Valdivieso, M. et al. Comparison of high-dose interleukin-2 with combined chemotherapy low-dose IL-2 in metastatic malignant melanoma. Proc Am soc Clin Oncol 1991, 10: 1031.
130. Blair, S., Flaherty, L., Valdiviaso, M. et al. Comparison of high dose interleukin-2 with combined chemotherapy low-dose IL2 in metastatic malignant melanoma. Proc Am Soc Clin Oncol Congr 1991, 10: 1031.
131. Demchak, P.A., Mier, J.W., Robert, N.J. et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 1991, 9: 1821-30.
132. Hamblin, T.J. Indomethacin, ranitidine, and interleukin-2 in melanoma. Lancet 1992, 340: 1044.
133. Richards, J.M., Mehta, N., Ramming, K. et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10: 1338-43.
134. Flaherty, L.E., Robinson, W., Redman, B.G. et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993, 71: 3520-5.
135. Atkins, M.B., O'Boyle, K.R., Sosman, J.A. et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994, 12: 1553-60.
136. Dorval, T., Negrier, S., Chevreau, C. et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre Ie Cancer Multicenter, parallel study. Cancer 1999, 85: 1060-6.
137. Legha, S.S., Ring, S., Eton, O. et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998, 16: 1752-9.
138. Proebstle, T.M., Fuchs, T., Scheibenbogen, C. et al. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res 1998, 8: 557-63.
139. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J. et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999, 17: 968-75.
140. Keilholz, U., Goey, S.H., Punt, C.J. et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997, 15: 2579-88.
141. Richards, J.M., Gale, D., Mehta, N. et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999, 17: 651-7.
142. O'Day, S.J., Gammon, G., Boasberg, P.D. et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999, 17: 2752-61.
143. McDermott, D.F., Mier, J.W., Lawrence, D.P. et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000, 6: 2201-8.
144. Gibbs, P., Iannucci, A., Becker, M. et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res 2000, 10: 171-9.
145. Atkins, M.B., Gollob, J.A., Sosman, J.A. et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002, 8: 3075-81.
146. Legha, S.S., Ring, S., Bedikian, A. et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CBD) and biotherapy using interleukin-2 and interferon-alfa. Ann Oncol 1996, 827-35.
147. Dorval, T., Negrier, S., Chevreau, C. et al. Results of a French multicentric randomized trial of chemoimmunotherapy with or without interferon in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1994, 13: 1347.
148. Atzpodien, J., López Hanninen, E., Kirchner, H. et al. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995, 31A: 876-81.
149. Bernengo, M.G., Doveil, G.C., Bertero, M. et al. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma - a pilot study. Melanoma Res 1996, 6: 257-65.
150. Thompson, J.A., Gold, P.J., Fefer, A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol 1997, 24(1 Suppl 4): S44-8.
151. Andres, P., Cupissol, D., Guillot, B. et al. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma. Eur J Dermatol 1998, 8: 235-9.
152. Dillman, R.O., Soori, G., Wiemann, M.C. et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: Final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000, 15: 487-94.
153. Atzpodien, J., Neuber, K., Kamanabrou, D. et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002, 86: 179-84.
154. Pawlak, W. et al. Biochemotherapy of metastatic malignant melanoma (MMM) with CVD-BIO. A phase II study. Proc Am Soc Clin Oncol Congr, 2002: Abstr 1404.
155. Johnston, S.R., Constenla, D.O., Moore, J. et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998, 77: 1280-6.
156. Ridolfi, R., Chiarion-Sileni, V., Guida, M. et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients, results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002, 20: 1600-7.
157. Flaherty, L.E., Atkins, M., Sosman, J. et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma, results of two phase II cytokine working group trials. J Clin Oncol 2001, 19: 3194-202.
158. Keilholz, U., Punt, C., Gore, M. et al. Dacarbazine, cisplatin and interferon-alfa with or without interleukin-2 in advanced melanoma, interim analysis of EORTC trial 18951. Proc Am Soc Clin Oncol 1999, 18: 530a.
159. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J. et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon-alfa2b. J Clin Oncol 1999, 17: 968-75.
160. Allen, R.E., Jr., Epstein, W.L. Melanoma therapy. Clin Dermatol 1992, 10: 317-25.
161. Maral, J. Long term follow-up of patients with metastatic malignant melanoma treated with continuous infusion II-2 alone or in combination. 8th Int Congr Anticancer Treatment 1998: 1560.
162. Eton, O., Legha, S.S., Bedikian, A.Y. et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma, results from a phase III randomized trial. J Clin Oncol 2002, 20: 2045-52.